Triplet Therapeutics scores $59 mln

Cambridge, Massachusetts-based Triplet Therapeutics Inc, a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, has secured $59 million in financing.

Cambridge, Massachusetts-based Triplet Therapeutics Inc, a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, has secured $59 million in financing. The investors include MPM Capital and Pfizer Ventures U.S. LLC, the venture capital arm of Pfizer Inc.

Source: Press Release